Skip to main content
. 2023 Mar 7;16(1):133–159. doi: 10.1016/j.jcmgh.2023.03.001

Figure 8.

Figure 8

Erastin effectively induced ferroptotic HCC cell death. (A) Cell proliferation rates of MHCC97L cells determined by cell counting daily were significantly suppressed by treatments of 2.5, 5, and 10 μM ferroptosis inducer erastin in dose-dependent manner. (B) BODIPY 581/591 C11 staining in MHCC97L cells revealed significant increase of lipid peroxidation from treatments of 2.5, 5, and 10 μM erastin in dose-dependent manner. (C) SYTOX Green (SG+) staining in MHCC97L cells revealed that treatments of 2.5, 5, and 10 μM erastin resulted in significant increase in cell death dose-dependently. (D) Ferroptotic Hepa1-6 cells induced by erastin pre-treatment were more frequently phagocytosed by BMDMs. (E) In vivo HCC tumors were induced via HDTVi of plasmids carrying Keap1KO/c-MycOE in C57BL/6N mice fed with HFD. (i) Administration of erastin through intrperitoneal injection significantly reduced HCC tumor size compared with vehicle (n = 6 mice per experimental group). Left: Representative picture of harvested tumors. Middle & Right: Quantifications of tumor mass and body weight of mice. (ii) Administration of erastin increased the number of monocytes, DCs and macrophages, while it decreased the number of CD4+ T cells and CD8+ T cells in HDTVi-induced HCC tumors. Error bars indicate mean ± SD. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001 vs vehicle or 0 μM as indicated. Student t test. E: Scale bar = 1 cm.